Abstract:Quantitative in vitro to in vivo extrapolation (QIVIVE) is broadly considered a prerequisite bridge from in vitro findings to a dose paradigm. Quality and relevance of cell systems are the first prerequisite for QIVIVE. Information-rich and mechanistic endpoints (biomarkers) improve extrapolations, but a sophisticated endpoint does not make a bad cell model a good one. The next need is reverse toxicokinetics (TK), which estimates the dose necessary to reach a tissue concentration that is active in vitro. The Johns Hopkins Center for Alternatives to Animal Testing (CAAT) has created a roadmap for animal-free systemic toxicity testing, in which the needs and opportunities for TK are elaborated, in the context of different systemic toxicities. The report was discussed at two stakeholder forums in Brussels in 2012 and in Washington in 2013; the key recommendations are summarized herein. Contrary to common belief and the Paracelsus paradigm of everything is toxic, the majority of industrial chemicals do not exhibit toxicity. Strengthening the credibility of negative results of alternative approaches for hazard identification, therefore, avoids the need for QIVIVE. Here, especially the combination of methods in integrated testing strategies is most promising. Two further but very different approaches aim to overcome the problem of modeling in vivo complexity: The human-on-a-chip movement aims to reproduce large parts of living organism's complexity via microphysiological systems, that is, organ equivalents combined by microfluidics. At the same time, the Toxicity Testing in the 21st Century (Tox-21c) movement aims for mechanistic approaches (adverse outcome pathways as promoted by Organisation for Economic Co-operation and Development (OECD) or pathways of toxicity in the Human Toxome Project) for high-throughput screening, biological phenotyping, and ultimately a systems toxicology approach through integration with computer modeling. These 21st century approaches also require 21st century validation, for example, by evidence-based toxicology. Ultimately, QIVIVE is a prerequisite for extrapolating Tox-21c such approaches to human risk assessment.

Cell cultures in drug discovery and development: The need of reliable in vitro-in vivo extrapolation for pharmacodynamics and pharmacokinetics assessment

Role of in vitro two-dimensional (2D) and three-dimensional (3D) cell culture systems for ADME-Tox screening in drug discovery and development: a comprehensive review

Application of Ivive and Pbpk Modeling in Prospective Prediction of Clinical Pharmacokinetics: Strategy and Approach During the Drug Discovery Phase with Four Case Studies

3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration

Three-Dimensional in Vitro Cell Culture Models in Drug Discovery and Drug Repositioning

Development of novel tools for the in vitro investigation of drug-induced liver injury

A new approach to assess drug sensitivity in cells for novel drug discovery

Perspectives on In Vitro to In Vivo Extrapolations

The Combination of Cell Cultured Technology and In Silico Model to Inform the Drug Development

Coupling of computer modeling with in vitro methodologies to reduce animal usage in toxicity testing

Complex in Vitro Model: A Transformative Model in Drug Development and Precision Medicine

Grafting of 3D Bioprinting to in Vitro Drug Screening: A Review

Three-Dimensional In Vitro Cell Culture Models for Efficient Drug Discovery: Progress So Far and Future Prospects

Cell Line Culture in Pharmaceutical Development and Application: A Review

Three-dimensional Culture of Hepatocytes for Prediction of Drug-Induced Hepatotoxicity

A Microfluidic Perfusion Platform for In Vitro Analysis of Drug Pharmacokinetic-Pharmacodynamic (PK-PD) Relationships

Recent Advances on Cell Culture Platforms for In Vitro Drug Screening and Cell Therapies: From Conventional to Microfluidic Strategies

Drug Discovery Goes Three-Dimensional: Goodbye to Flat High-Throughput Screening?

A comprehensive overview of advanced dynamic in vitro intestinal and hepatic cell culture models

3D Cell Cultures: Evolution of an Ancient Tool for New Applications

An Evaluation of the Replacement of Animal-derived Biomaterials in Human Primary Cell Culture